FT Options’s Lipocine LPCN Stock Holding History

FT Options’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-371	Closed	-$4K	–	422
2016 Q2	$4K	Buy	+371	New	+$57.5K	﹤0.01%	310

Other funds holding LPCN

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

FT Options's LPCN Position: Q3 2016 in Review

FT Options sold out of Lipocine (LPCN) in Q3 2016, closing a stake of 106 shares — an estimated $5K sold.

FT Options first reported a position in LPCN in Q2 2016 and held it in 1 quarter. The position peaked at $5K in Q2 2016. 47 funds tracked by Wall St. Rank hold LPCN as of Q3 2016.

FT Options reported no remaining Lipocine position as of Q3 2016 after selling out during the quarter.
FT Options sold 106 Lipocine shares in Q3 2016, an estimated $5K.
FT Options first reported a position in Lipocine in Q2 2016 and held it in 1 quarter.
FT Options's Lipocine position peaked at $5K in Q2 2016.
47 funds tracked by Wall St. Rank held Lipocine as of Q3 2016.

Based on FT Options's 13F filing for Q3 2016, filed 10 Nov 2016.